Search Results
Your search for ASCO ,ASCO matches 21858 pages
Showing 51 - 100
Dory Abelman, PhD(c), HBHSc, on Newly Diagnosed Multiple Myeloma: Ultradeep Whole-Genome Sequencing of cfDNA
Dory Abelman, PhD(c), HBHSc, of the University of Toronto, discusses findings that support the feasibility of ultradeep cell-free DNA whole-genome sequencing for comprehensive genomic profiling in patients with multiple myeloma, which may be a less invasive alternative to bone marrow biopsy...
New Pooled Analysis Strengthens Case for MRD as Surrogate Endpoint in AML
Measurable residual disease (MRD), regardless of the method of assessment, is a robust individual-level predictor for overall survival among patients with acute myeloid leukemia (AML) who have already received induction therapy, according to findings from a pooled analysis presented at the 2025...
Guillermo Garcia-Manero, MD, on MDS: Research Highlights From ASH 2025
Guillermo Garcia-Manero, MD, of The University of Texas MD Anderson Cancer Center, reviews data from three abstracts in myelodysplastic syndromes (MDS) presented at this year’s meeting: outcomes from the phase III VERONA trial of venetoclax with azacitidine vs placebo with azacitidine in patients...
Benjamin Diamond, MD, on a Novel Quadruplet for Relapsed/Refractory Multiple Myeloma
Benjamin Diamond, MD, of the University of Miami, describes findings from the single-center phase II REKINDLE trial, which looked at the combination regimen of iberdomide, carfilzomib, daratumumab, and dexamethasone in patients with early relapsed/refractory multiple myeloma (Abstract 251).
ASTRO Marks Former President Biden’s Prostate Cancer Treatment Milestone
The American Society for Radiation Oncology (ASTRO) congratulates former President Joe Biden on completing his course of radiation therapy, which he marked by ringing the ceremonial bell alongside his radiation oncology care team. “President Biden’s bell-ringing milestone underscores the vital role ...
Krina Patel, MD, MSc, on Anitocabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma
Krina Patel, MD, MSc, of The University of Texas MD Anderson Cancer Center, provides updated results from the fully enrolled, ongoing iMMagine-1 phase II registrational trial of anitocabtagene autoleucel, an autologous anti-BCMA CAR T-cell therapy with a novel D-domain binder. The agent is under...
Amir Fathi, MD, on Newly Diagnosed AML: Azacitidine and Venetoclax vs Conventional Induction Chemotherapy
Amir Fathi, MD, of Massachusetts General Hospital, discusses data from the phase II PARADIGM trial, which prospectively tested whether azacitidine plus venetoclax was superior to intensive induction chemotherapy in fit patients with newly diagnosed acute myeloid leukemia (AML)—and could challenge...
Othman Al-Sawaf, MD, PhD, on Previously Untreated CLL: Fixed-Duration vs Continuous Targeted Treatment
Othman Al-Sawaf, MD, PhD, of the University Hospital of Cologne, presents results from the phase III CLL17 trial, which compared continuous ibrutinib monotherapy to fixed-duration venetoclax plus obinutuzumab to fixed-duration venetoclax plus ibrutinib for previously untreated patients with chronic ...
Fixed-Duration Doublet Noninferior to Continuous Ibrutinib in CLL
Early results from the CLL17 trial show that fixed-duration doublet regimens with venetoclax are noninferior to continuous ibrutinib therapy, with similar 3-year progression-free survival rates, for patients with chronic lymphocytic leukemia (CLL), according to findings presented at the 2025...
Anand Patel, MD, on Ph-Positive ALL: TKI Plus Inotuzumab Ozogamicin–Based Therapy
Anand Patel, MD, of the University of Chicago, discusses results from a phase II trial that showed tyrosine kinase inhibitor plus inotuzumab ozogamicin–based therapy resulted in major molecular response in patients newly diagnosed with Philadelphia chromosome (Ph)-positive acute lymphoblastic...
Ibrahim Aldoss, MD, on Older Adults With B-Cell ALL: CD19 CAR T-Cell Therapy
Ibrahim Aldoss, MD, of City of Hope, presents findings from a small, single-center study of patients aged 55 years and older with B-cell acute lymphoblastic leukemia (ALL) in first complete remission who were treated with CD19-directed CAR T-cell therapy. Researchers found the therapy was safe,...
Valeria Santini, MD, on Imetelstat for Lower-Risk MDS: Long-Term Outcomes From the IMerge Trial
The telomerase inhibitor imetelstat was approved for the treatment of certain patients with lower-risk myelodysplastic syndromes (MDS) based on the results of the phase III IMerge trial. Valeria Santini, MD, of the University of Florence, provides updates on secondary endpoints, including overall...
Jayastu Senapati, MBBS, on B-Cell ALL: Brexucabtagene Autoleucel as Consolidation Therapy
Jayastu Senapati, MBBS, of The University of Texas MD Anderson Cancer Center, presents initial results from a phase II trial of brexucabtagene autoleucel as consolidation therapy in front-line high-risk B-cell acute lymphoblastic leukemia (B-ALL) or relapsed/refractory B-ALL after cytoreduction...
Aaron Logan, MD, PhD, on Relapsed/Refractory B-Cell ALL: Real-World Data on Brexucabtagene Autoleucel and Transplant
Aaron Logan, MD, PhD, of UCSF Health, discusses research examining the effect of transplant before or after treatment with brexucabtagene autoleucel in the real world for adult patients with relapsed or refractory Philadelphia chromosome–negative B-cell acute lymphoblastic leukemia (ALL) (Abstract...
Jack Khouri, MD, on Multiple Myeloma: Burixafor and Propranolol With G-CSF Before Transplant
Jack Khouri, MD, of Cleveland Clinic, describes the findings of a phase II trial which investigated the safety and efficacy of burixafor (GPC-100), a potent and selective small -molecule antagonist of CXCR4, and propranolol with granulocyte colony-stimulating factor (G-CSF) for the mobilization of...
Final Overall Survival Confirms Benefit of Durvalumab Plus FLOT in Resectable Gastric and Gastroesophageal Junction Adenocarcinomas
The addition of the PD-L1–targeting monoclonal antibody durvalumab to conventional perioperative chemotherapy with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) resulted in a statistically significant and clinically meaningful improvement in overall survival, with benefit seen...
FDA Approves CAR T-Cell Therapy for Relapsed/Refractory Marginal Zone Lymphoma
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved the CD19-directed chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (Breyanzi) for the treatment of adult patients with relapsed or refractory marginal zone lymphoma who have received at least two prior...
Renuka Iyer, MD, Named New Chief Medical Officer for NCCN
The National Comprehensive Cancer Network® (NCCN®) has announced the hiring of Renuka Iyer, MD, as the new Chief Medical Officer (CMO) for the organization. Dr. Iyer has a long history of leadership and innovation in oncology. She currently serves as a Professor of Oncology for Roswell Park...
ASCO Statement on the Departure of Richard Pazdur, MD, From the FDA
Richard Pazdur, MD, Director of the Center for Drug Evaluation and Research at the U.S. Food and Drug Administration (FDA) and former long-time head of the FDA Oncology Center of Excellence (OCE), is leaving the FDA. Dr. Pazdur has served the FDA for 26 years and is an expert in drug regulation....
Mammography-Based Outreach Increases Lung Cancer Screening Enrollment in Eligible Women
Women who undergo mammography to screen for breast cancer can be reviewed and recommended for additional lung cancer screening, thereby increasing enrollment, according to the results of a study published in the Journal of the American College of Radiology. The study, called Coordinate a Lung...
FDA Grants Traditional Approval to Pirtobrutinib for CLL/SLL
On December 3, the U.S. Food and Drug Administration (FDA) granted traditional approval to pirtobrutinib (Jaypirca), a noncovalent Bruton’s tyrosine kinase (BTK) inhibitor, for adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have...
Survey Finds Global Embrace of Integrative Cancer Care
Around the world, doctors, nurses, and pharmacists are turning to evidence-based integrative approaches such as acupuncture, yoga, exercise, massage, and nutrition counseling to help people with cancer manage the harsh side effects of treatment, according to the results of a recent survey. The new...
AYA Cancers: Survival for Metastatic Recurrence Worse Than De Novo Metastatic Disease
Almost 10% of adolescents and young adults (AYAs) diagnosed with earlier-stage cancer develop metastatic disease, and survival outcomes were found to be worse for patients who developed metastatic recurrence compared with those who had metastatic disease at initial diagnosis for almost all analyzed ...
Retrospective Review Shows Persistent Breast Cancer Burden in Younger Women
Up to 24% of breast cancers diagnosed in an 11-year period between seven outpatient facilities around New York were found in women aged 18 to 49 years, according to findings presented during the 2025 Annual Meeting of the Radiological Society of North America (RSNA; Abstract S5-SSBR02-1). “This...
Domenica Lorusso, MD, PhD, on Platinum-Resistant Ovarian Cancer: Relacorilant and Nab-Paclitaxel in Pretreated Patients
Domenica Lorusso, MD, PhD, of Humanitas University, discusses results of a preplanned analysis from the ROSELLA trial. In the phase III study, the addition of relacorilant to nab-paclitaxel significantly prolonged progression-free survival and showed a clinically meaningful improvement in overall...
Image-Only AI Model Outperforms Breast Density Assessment for 5-Year Breast Cancer Risk Stratification
An image-only artificial intelligence (AI) model demonstrated stronger and more precise risk stratification than breast density assessment for predicting 5-year risk for developing breast cancer, according to findings from a study presented at the 2025 Annual Meeting of the Radiological Society of...
Andrew R. Clamp, MD, PhD, on High-Risk Ovarian Cancer: Weekly Dose-Dense and Every-3-Week Chemotherapy Plus Bevacizumab
Andrew R. Clamp, MD, PhD, of The Christie NHS Foundation Trust, reviews results of the phase III ICON8B trial, which found that in patients with high-risk stage III to IV epithelial ovarian cancer, the use of dose-dense weekly paclitaxel in combination with every-3-week carboplatin and bevacizumab...
FDA Approves Durvalumab With FLOT for Resectable Gastric/GEJ Adenocarcinoma
On November 25, 2025, the U.S. Food and Drug Administration (FDA) approved durvalumab (Imfinzi) in combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy as neoadjuvant and adjuvant treatment, followed by single-agent durvalumab, for the treatment of adult...
JADPRO Live 2025: United in Care
Oncology advanced practitioners summarize sessions from JADPRO Live 2025, a continuing education conference that took place in National Harbor, Maryland, from October 23 through 26. The agenda featured a diverse lineup of practice management topics in solid tumors, hematologic malignancies, and...
As a Cancer Survivor, My Main Worry Now Is Affording Health Insurance
Until 3 years ago, cancer was so utterly frightening to me that I avoided discussing the disease or even mentioning the word as much as possible. I sympathized with a friend when she was diagnosed with lung cancer, but I never expected to be in her position. I’m a never-smoker, and except for a...
AI Simplifies Patients' Comprehension of CT Reports—but Errors Are Possible
Simplified oncologic computed tomography (CT) reports using large language models (LLMs) enabled patients to better understand the results of their restaging CT scans and reduced overall reading burden, according to the results of a study published in Radiology. However, the study also revealed...
New Approvals in Hematologic Malignancies, Skin Cancer, and Small Cell Lung Cancer
Here are brief reports on four oncology approvals by the U.S. Food and Drug Administration (FDA) in October 2025: • Menin Inhibitor in NPM1-Positive AML : On October 24, 2025, the FDA approved revumenib (Revuforj), a menin inhibitor, for the treatment of relapsed or refractory acute myeloid...
ASTRO Recognizes 2025 Award Recipients for Excellence in Radiation Oncology
During its recent Annual Meeting, the American Society for Radiation Oncology (ASTRO) honored the recipients of its 2025 Gold Medal awards and other prestigious distinctions. Here, The ASCO Post celebrates the achievements of these leading radiation oncology experts. Gold Medal The Gold Medal is...
How an Endowed Chair in Cord Blood Research Is Providing New Hope for Patients With High-Risk Leukemia
In 2016, Filippo Milano, MD, PhD, Associate Professor, Translational Science and Therapeutics Division, and Director of the Cord Blood Transplant Program at Fred Hutchinson Cancer Center in Seattle, published the results of his landmark study investigating whether an alternative stem cell donor...
Memorial Sloan Kettering Names Recipients of 2025 Paul Marks Prize for Cancer Research
Memorial Sloan Kettering Cancer Center (MSK) will award three cancer researchers with this year’s Paul Marks Prize for Cancer Research. The prize, named in honor of former MSK president Paul Marks, MD, recognizes a new generation of leaders who are making significant contributions to the...
ASCO Election for Open Leadership Positions
The ASCO Nominating Committee has selected 13 distinguished members as candidates for open leadership positions within the Society. President-Elect: Deb Schrag, MD, MPH, FASCO, Memorial Sloan Kettering Cancer Center Dr. Schrag is a gastrointestinal medical oncologist who currently serves as Chair...
Significant Medicare Physician Reimbursement Methodology Changes Finalized for 2026
The Centers for Medicare & Medicaid Services (CMS) released the Medicare Physician Fee Schedule final rule for 2026 on October 31, 2025.1 The rule finalizes physician reimbursement and policy reforms under the Physician Fee Schedule as well as changes to reporting requirements and policy...
Project DISARM: New Cancer Mission Emphasizes Risk Assessment and Early Detection of Ovarian Cancer
Often referred to as a “silent killer,” ovarian cancer is the most lethal of female cancers. Issues of late detection and poor survival rates continue to persevere, leading to increasing levels of incidence and mortality. Data from the World Ovarian Cancer Coalition have stressed that ovarian...
Zanzalintinib Plus Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer
The phase III STELLAR-303 trial evaluated the anti-VEGFR–related multitargeted tyrosine kinase inhibitor zanzalintinib in combination with the PD-L1 inhibitor atezolizumab vs the multikinase inhibitor regorafenib in patients with previously treated non–microsatellite instability (MSI)–high...
Icahn School of Medicine Family Center for Caregiving Launches Website to Further Reach and Broaden Mission
Allison J. Applebaum, PhD, FAPOS, recently announced the launch of the website for the Steven S. Elbaum Family Center for Caregiving at the Icahn School of Medicine at Mount Sinai in New York (www.mountsinai.org/care/palliative-care/elbaum-center-caregiving). Dr. Applebaum is Director of the...
European Society for Medical Oncology Congress 2025 Meeting Highlights
The European Society for Medical Oncology (ESMO) Congress 2025 in Berlin featured many important trials with the potential to significantly influence clinical practice and improve outcomes for patients with multiple tumor types. These studies highlighted the benefits of novel treatment combination...
ASTRO Publishes First Clinical Guideline on Radiation Therapy for Gastric Cancer
A new clinical guideline from the American Society for Radiation Oncology (ASTRO) is the first to focus on radiation therapy for patients with gastric cancer. The recommendations outline radiation therapy’s role in multidisciplinary care, including best practices for patient selection, integration...
FDA Approves Pembrolizumab With Enfortumab Vedotin-ejfv for Muscle-Invasive Bladder Cancer
On November 21, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) or the subcutaneous formulation pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) in combination with enfortumab vedotin-ejfv (Padcev) as neoadjuvant treatment followed by adjuvant treatment...
Pembrolizumab Plus Weekly Paclitaxel Improves Survival Outcomes in Platinum-Resistant Recurrent Ovarian Cancer
The addition of the PD-1 inhibitor pembrolizumab to weekly paclitaxel, with or without the VEGFA-targeted bevacizumab, significantly improved progression-free survival and overall survival in patients with platinum-resistant recurrent ovarian cancer, in the randomized, double-blind, phase III...
Large AI Breast Cancer Screening Trial Increases Detection Rate by 20%
Using an artificial intelligence (AI)–integrated workflow, DeepHealth, in computer-aided detection of breast cancer from digital breast tomosynthesis exams found 21.6% more cases than the usual standard of care, according to findings from the AI-Supported Safeguard Review Evaluation (ASSURE) study...
Geriatric Assessment–Guided Approach to Treatment Intensity in Older Adults With Acute Myeloid Leukemia
“Pretreatment geriatric assessment in older adults with acute myeloid leukemia is feasible, can identify several functional impairments, and [can] guide the selection of treatment intensity,” resulting in low rates of early mortality, according to Vijaya R. Bhatt, MBBS, MS, of the University of...
Reducing the Barriers to Receiving CAR T-Cell Therapy for Patients With Hematologic Malignancies
Chimeric antigen receptor (CAR) T-cell therapy has transformed treatment for patients with hematologic malignancies, achieving unprecedented responses in some patients, especially those diagnosed with relapsed/refractory B-cell acute lymphocytic leukemia, non-Hodgkin lymphoma, and multiple...
ASTRO Experts Comment on the Results of the SUPREMO Trial
A large international study published by Kunkler et al in The New England Journal of Medicine examined whether chest wall radiation therapy after mastectomy improves survival for patients with early-stage breast cancer. The study, known as the SUPREMO trial, found no overall survival difference...
Could Opportunistic Salpingectomy Prevent Ovarian Cancer in Postreproductive Women?
Known as “the silent killer” due to its lack of symptoms and reliable screening tests, ovarian cancer remains one of the deadliest gynecologic cancers, claiming more than 12,000 lives annually. At a recent meeting, experts said that performing a single preventive procedure within general surgery...
Traditional Approval Granted to Tarlatamab-dlle for Extensive-Stage SCLC
On November 19, the U.S. Food and Drug Administration (FDA) granted traditional approval to tarlatamab-dlle (Imdelltra), a DLL3-targeting bispecific T-cell engager, for adults with extensive-stage small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy....
